Impact of preoperative anemia on relapse and survival in breast cancer patients

BMC Cancer

YingJun Zhang³  YuYang Chen²  DongTai Chen³  Yu Jiang³  Wan Huang³  HanDong Ouyang³  Wei Xing³  MuSheng Zeng¹  XiaoMing Xie⁴  Weian Zeng³ 

[1] State Key Laboratory in South China, Sun Yat-Sen University Cancer Center, Guangzhou, PR China

[2] Department of Cardiology, Sun Yat-sen Memorial Hospital of Sun Yat-Sen University, Guangzhou, PR China

[3] Anesthesiology Department, State Key Laboratory in South China, Sun Yat-Sen University Cancer Center, 651 Dongfeng East Road, Guangzhou, PR China

[4] Department of Breast Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, PR China

关键词: Hypoxia;    Survival;    Relapse;    Breast cancer;    Preoperative anemia;   

Others  :  1118178
DOI  :  10.1186/1471-2407-14-844

 received in 2014-07-09, accepted in 2014-11-04,  发布年份 2014

【 摘 要 】

Background

Previous studies have shown that preoperative anemia is correlated with the prognoses of various solid tumors. This study was performed to determine the effect of preoperative anemia on relapse and survival in patients with breast cancer.

Methods

A total of 2960 patients with breast cancer who underwent surgery between 2002 and 2008 at the Sun Yat-sen University Cancer Center (Guangzhou, PR China) were evaluated in a retrospective analysis. A total of 2123 qualified patients were divided into an anemic group [hemoglobin (Hb) < 12.0 g/dL, N = 535)] and a nonanemic group (Hb ≥ 12.0 g/dL, N = 1588). The effects of anemia on local relapse-free survival (LRFS), lymph node metastasis-free survival (LNMFS), distant metastasis-free survival (DMFS), relapse-free survival (RFS), and overall survival (OS) were assessed using Kaplan–Meier analysis. Independent prognostic factors were identified in the final multivariate Cox proportional hazards regression model.

Results

Among the 2123 women who qualified for the analysis, 535 (25.2%) had a Hb level < 12.0 g/dL. The Kaplan–Meier curves showed that anemic patients had worse LRFS, LNMFS, DMFS, RFS, and OS than nonanemic patients, even in the same clinical stage of breast cancer. Cox proportional hazards regression model indicated that preoperative anemia was an independent prognostic factor of LRFS, LNMFS, DMFS, RFS, and OS for patients with breast cancer.

Conclusions

Preoperative anemia was independently associated with poor prognosis of patients with breast cancer.

【 授权许可】

   
2014 Zhang et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Knight K, Wade S, Balducci L: Prevalence and outcomes of anemia in cancer: a systematic review of the literature. Am J Med 2004, 116(Suppl 7A):11S-26S.
• [2]Hu K, Harrison LB: Impact of anemia in patients with head and neck cancer treated with radiation therapy. Curr Treat Options Oncol 2005, 6(1):31-45.
• [3]Choi YS, Yi CM, Sin JI, Ye GW, Shin IH, Lee TS: Impact of hemoglobin on survival of cervical carcinoma patients treated with concurrent chemoradiotherapy is dependent on lymph node metastasis findings by magnetic resonance imaging. Int J Gynecol Cancer 2006, 16(5):1846-1854.
• [4]Grogan M, Thomas GM, Melamed I, Wong FL, Pearcey RG, Joseph PK, Portelance L, Crook J, Jones KD: The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 1999, 86(8):1528-1536.
• [5]Dunphy EP, Petersen IA, Cox RS, Bagshaw MA: The influence of initial hemoglobin and blood pressure levels on results of radiation therapy for carcinoma of the prostate. Int J Radiat Oncol Biol Phys 1989, 16(5):1173-1178.
• [6]Caro JJ, Salas M, Ward A, Goss G: Anemia as an independent prognostic factor for survival in patients with cancer: a systemic, quantitative review. Cancer 2001, 91(12):2214-2221.
• [7]Musallam KM, Tamim HM, Richards T, Spahn DR, Rosendaal FR, Habbal A, Khreiss M, Dahdaleh FS, Khavandi K, Sfeir PM, Soweid A, Hoballah JJ, Taher AT, Jamali FR: Preoperative anaemia and postoperative outcomes in non-cardiac surgery: a retrospective cohort study. Lancet 2011, 378(9800):1396-1407.
• [8]Soerjomataram I, Louwman MW, Ribot JG, Roukema JA, Coebergh JW: An overview of prognostic factors for long-term survivors of breast cancer. Breast Cancer Res Treat 2008, 107(3):309-330.
• [9]Cianfrocca M, Goldstein LJ: Prognostic and predictive factors in early-stage breast cancer. Oncologist 2004, 9(6):606-616.
• [10]Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H: Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol 2010, 28(10):1684-1691.
• [11]Kandemir EG, Mayadagli A, Turken O, Yaylaci M, Ozturk A: Pre-treatment haemoglobin concentration is a prognostic factor in patients with early-stage breast cancer. J Int Med Res 2005, 33(3):319-328.
• [12]Boehm DU, Lebrecht A, Schmidt M, Siggelkow W, Lindner C, Litz A, Ulbrich E, Koelbl H: Prognostic impact of haemoglobin levels in breast cancer. Anticancer Res 2007, 27(2):1223-1226.
• [13]Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, Borgen PI, Clark G, Edge SB, Hayes DF, Hughes LL, Hutter RV, Morrow M, Page DL, Recht A, Theriault RL, Thor A, Weaver DL, Wieand HS, Greene FL: Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol 2002, 20(17):3628-3636.
• [14]Cordella C, Luebbers HT, Rivelli V, Gratz KW, Kruse AL: An evaluation of the preoperative hemoglobin level as a prognostic factor for oral squamous cell carcinoma. Head Neck Oncol 2011, 3:35. BioMed Central Full Text
• [15]Gilreath JA, Stenehjem DD, Rodgers GM: Diagnosis and treatment of cancer-related anemia. Am J Hematol 2014, 89(2):203-212.
• [16]Wilson J, Yao GL, Raftery J, Bohlius J, Brunskill S, Sandercock J, Bayliss S, Moss P, Stanworth S, Hyde C: A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment. Health Technol Assess 2007, 11(13):1-202.
• [17]Thompson CA, Steensma DP: Pure red cell aplasia associated with thymoma: clinical insights from a 50-year single-institution experience. Br J Haematol 2006, 135(3):405-407.
• [18]Dubsky P, Sevelda P, Jakesz R, Hausmaninger H, Samonigg H, Seifert M, Denison U, Mlineritsch B, Steger G, Kwasny W, Stöger H, Bartsch R, Stierer M, Taucher S, Fridrik M, Schippinger W, Greil R, Pötter R, Gnant M, Austrian Breast and Colorectal Cancer Study Group: Anemia is a significant prognostic factor in local relapse-free survival of premenopausal primary breast cancer patients receiving adjuvant cyclophosphamide/methotrexate/5-fluorouracil chemotherapy. Clin Cancer Res 2008, 14(7):2082-2087.
• [19]Peters-Engl C, Cassik P, Schmidt I, Denison U, Medl M, Pokieser W, Sevelda P: Impact of haemoglobin levels during adjuvant chemotherapy on the survival of patients with primary breast cancer. Acta Oncol 2005, 44(2):129-133.
• [20]Vaupel P: The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9(Suppl 5):10-17.
• [21]Harrison L, Blackwell K: Hypoxia and anemia: factors in decreased sensitivity to radiation therapy and chemotherapy? Oncologist 2004, 9(Suppl 5):31-40.
• [22]Vaupel P, Mayer A, Hockel M: Impact of hemoglobin levels on tumor oxygenation: the higher, the better? Strahlenther Onkol 2006, 182(2):63-71.
• [23]Vaupel P, Mayer A, Briest S, Hockel M: Hypoxia in breast cancer: role of blood flow, oxygen diffusion distances, and anemia in the development of oxygen depletion. Adv Exp Med Biol 2005, 566:333-342.
• [24]Vaupel P, Harrison L: Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004, 9(Suppl 5):4-9.
• [25]Teicher BA: Acute and chronic in vivo therapeutic resistance. Biochem Pharmacol 2009, 77(11):1665-1673.
• [26]Harrison LB, Chadha M, Hill RJ, Hu K, Shasha D: Impact of tumor hypoxia and anemia on radiation therapy outcomes. Oncologist 2002, 7(6):492-508.
• [27]Vaupel P, Thews O, Hoeckel M: Treatment resistance of solid tumors: role of hypoxia and anemia. Med Oncol 2001, 18(4):243-259.
• [28]Vaupel P, Mayer A, Briest S, Hockel M: Oxygenation gain factor: a novel parameter characterizing the association between hemoglobin level and the oxygenation status of breast cancers. Cancer Res 2003, 63(22):7634-7637.
• [29]Vaupel P, Briest S, Hockel M: Hypoxia in breast cancer: pathogenesis, characterization and biological/therapeutic implications. Wien Med Wochenschr 2002, 152(13–14):334-342.
• [30]Hockel M, Vaupel P: Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. J Natl Cancer Inst 2001, 93(4):266-276.
• [31]Bos R, Zhong H, Hanrahan CF, Mommers EC, Semenza GL, Pinedo HM, Abeloff MD, Simons JW, van Diest PJ, van der Wall E: Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J Natl Cancer Inst 2001, 93(4):309-314.
• [32]Zhou J, Schmid T, Schnitzer S, Brune B: Tumor hypoxia and cancer progression. Cancer Lett 2006, 237(1):10-21.
• [33]Liao D, Johnson RS: Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev 2007, 26(2):281-290.
• [34]Varlotto J, Stevenson MA: Anemia, tumor hypoxemia, and the cancer patient. Int J Radiat Oncol Biol Phys 2005, 63(1):25-36.
• [35]Vaupel P, Mayer A: Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26(2):225-239.
• [36]Vleugel MM, Greijer AE, Shvarts A, van der Groep P, van Berkel M, Aarbodem Y, van Tinteren H, Harris AL, van Diest PJ, van der Wall E: Differential prognostic impact of hypoxia induced and diffuse HIF-1alpha expression in invasive breast cancer. J Clin Pathol 2005, 58(2):172-177.
• [37]Vaupel P: Prognostic potential of the pre-therapeutic tumor oxygenation status. Adv Exp Med Biol 2009, 645:241-246.
• [38]Rodgers GM: A perspective on the evolution of management of cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012, 10(4):434-437.
• [39]Rodgers GR, Becker PS, Blinder M, Cella D, Chanan-Khan A, Cleeland C, Coccia PF, Djulbegovic B, Gilreath JA, Kraut EH, Matulonis UA, Millenson MM, Reinke D, Rosenthal J, Schwartz RN, Soff G, Stein RS, Vlahovic G, Weir AB 3rd: Cancer- and chemotherapy-induced anemia. J Natl Compr Canc Netw 2012, 10(5):628-653.
• [40]Khorana AA, Francis CW, Blumberg N, Culakova E, Refaai MA, Lyman GH: Blood transfusions, thrombosis, and mortality in hospitalized patients with cancer. Arch Intern Med 2008, 168(21):2377-2381.